Altimmune (ALT) Interest Expenses (2010 - 2026)

Altimmune (ALT) has 17 years of Interest Expenses data on file, last reported at $2.7 million in Q1 2026.

• On a quarterly basis, Interest Expenses rose 7.19% year-over-year to $2.7 million in Q1 2026; TTM through Mar 2026 was $2.7 million, a 7.19% increase from a year earlier, with the FY2025 full-year figure at $2.9 million, down 97.27% from the prior year.
• Interest Expenses for Q1 2026 stood at $2.7 million, up from $840000.0 in the prior quarter.
• Over the last five years, Interest Expenses for ALT reached as high as $15.1 million in Q1 2024 and fell as low as -$392000.0 in Q4 2022.
• Historically, Interest Expenses has averaged $2.0 million across 5 years, with a median of $726000.0 in 2023.
• Across the five-year window, Interest Expenses tumbled 532.26% in 2022 and jumped 14979.0% in 2024, its largest moves.
• Year by year, Interest Expenses stood at -$392000.0 in 2022, then rose by 6.89% to -$365000.0 in 2023, then jumped by 234.79% to $492000.0 in 2024, then surged by 70.73% to $840000.0 in 2025, then surged by 219.4% to $2.7 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $2.7 million in Q1 2026, $840000.0 in Q4 2025, and $1.5 million in Q3 2025.